Product development

Synaffix is a biotechnology company enabling highly-competitive targeted cancer therapeutics using its site-specific antibody-drug conjugate (ADC) technology platform. The platform consistently delivers more effective and better tolerated ADCs compared to all 3 major clinical-stage technologies.

The business model of Synaffix is technology out-licensing where granted patents provide end-to-end protection of the technology and resulting product candidates thru at least 2035.

We anticipate the first-in-human studies evaluating Synaffix ADC technology to be initiated by our partners in 2018.

Area of work

Oncology, Antibody Drug Conjugates

News from Synaffix

Synaffix ADC Technology enters the clinic

17 Jan 19
READ MORE

Synaffix Announces License Agreement with Mersana Therapeutics

08 Jan 19
READ MORE

Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States

16 May 17
READ MORE